In vitro basis for treatment with hypomethylating agents and histone deacetylase inhibitors: can epigenetic changes be used to monitor treatment?

Steven D. Gore

Research output: Contribution to journalArticle

Abstract

Hematopoietic disorders such as myelodysplastic syndromes (MDS) show a high frequency of methylation of tumor suppressor genes. DNA methyltransferase (DNMT) inhibitors such as azacitidine and decitabine are used to target DNA methylation in MDS patients. Combining these drugs with histone deacetylase (HDAC) inhibitors in vitro resulted in synergistic tumor suppressor gene re-expression. Several phase I trials have examined methylation, gene expression and DNA damage as markers of clinical response to DNMT and HDAC inhibitors, with conflicting results. Trials are ongoing to investigate early methylation changes and DNA damage markers to understand the mechanisms of these drugs and as potential predictors of clinical response.

Original languageEnglish (US)
Pages (from-to)S2-S6
JournalLeukemia Research
Volume33
Issue numberSUPPL. 2
DOIs
StatePublished - Dec 1 2009

Keywords

  • Azacitidine
  • Cancer epigenetics
  • DNA methyltransferase inhibitors
  • Histone deacetylase inhibitors
  • Myelodysplastic syndromes treatment
  • Predictors of response

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'In vitro basis for treatment with hypomethylating agents and histone deacetylase inhibitors: can epigenetic changes be used to monitor treatment?'. Together they form a unique fingerprint.

  • Cite this